Expression of phosphorylated Akt/mTOR and clinical significance in human ameloblastoma

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 4, 2015, Pages 5236-5244

  Li, Ning ^a,b   Sui, Jianfu ^b   Liu, Hao ^a   Zhong, Ming ^a   Zhang, Min ^a   Wang, Yan ^a   Hao, Fengyu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b No 202 Hospital of PLA   (China)

Author keywords

Akt; Human ameloblastoma; Oral squamous cell carcinoma

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B;

ADULT; AMELOBLASTOMA; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SPECTROPHOTOMETRY; WESTERN BLOTTING;

EID: 84935893529     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Cully M, You H, Levine AJ and Mak TW. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 184-192.
2. Rosen N and She QB. AKT and cancer-is it all mTOR? Cancer Cell 2006; 10: 254-256.
3. Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M and Tamanoi F. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci U S A 2007; 104: 3514-3519.
4. Takahashi K, Murakami M and Yamanaka S. Role of the phosphoinositide 3-kinase pathway in mouse embryonic stem (ES) cells. Biochem Soc Trans 2005; 33: 1522-1525.
5. Hay N and Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945.
6. Jiang H, Xv ZF, Qiu XH, Cao HF and Tang L. Expression of AKT and PTEN Protein and Their Relationship with Clinic Characteristics of Esophageal Carcinoma. Chin J Cancer Biother 2003; 10: 265-268.
7. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S and Ghosh PM. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004; 64: 5232-5236.
8. Nakanishi K, Sakamoto M, Yamasaki S, Todo S and Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005; 103: 307-312.
9. Roca S, Quivy A, Gross-Goupil M, Bernhard JC, De Clermont H and Ravaud A. Efficacy of re-challenging metastatic renal cell carcinoma with mTOR inhibitors. Acta Oncol 2011; 50: 1135-1136.
10. Min YH, Cheong JW, Kim JY, Eom JI, Lee ST, Hahn JS, Ko YW and Lee MH. Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 2004; 64: 5225-5231.
11. Xu G, Zhang W, Bertram P, Zheng XF and McLeod H. Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 2004; 24: 893-900.
12. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL and Reddy SA. The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun 2005; 331: 295-302.
13. Hanada M, Feng J and Hemmings BA. Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 2004; 1697: 3-16.
14. Gagnon V, St-Germain ME, Parent S and Asselin E. Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1. Int J Oncol 2003; 23: 803-810.
15. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J and Lowe SW. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 2004; 428: 332-337.
16. Murillo H, Huang H, Schmidt LJ, Smith DI and Tindall DJ. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001; 142: 4795-4805.
17. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004; 15: 171-176.
18. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, Muschel RJ and McKenna WG. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 2003; 56: 846-853.
19. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H and Sawyers CL. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001; 98: 10314-10319.
20. Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA and Aguiar RCT. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma. Blood 2005; 105: 308-316.
21. Wang L, Fortney JE and Gibson LF. Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt. Leuk Res 2004; 28: 733-742.
22. Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, Morris SW, Wasik MA and Skorski T. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001; 61: 2194-2199.